Literature DB >> 22652522

Community-associated Panton-Valentine leukocidin-negative meticillin-resistant Staphylococcus aureus clone (ST72-MRSA-IV) causing healthcare-associated pneumonia and surgical site infection in Korea.

E-J Joo1, D R Chung, Y E Ha, S Y Park, S-J Kang, S H Kim, C-I Kang, K R Peck, N Y Lee, K S Ko, J-H Song.   

Abstract

BACKGROUND: Community-associated meticillin-resistant Staphylococcus aureus (CA-MRSA) has emerged as an important pathogen worldwide in a continent-specific manner. Clinical characteristics of infections caused by CA-MRSA other than USA300, especially in healthcare settings, have not been well established. AIM: To conduct a retrospective cohort study to determine the clinical characteristics of infections caused by Panton-Valentine leukocidin (PVL)-negative, multilocus sequence type (ST) 72 staphylococcal cassette chromosome mec (SCCmec) type IV, a major CA-MRSA clone in Korea.
METHODS: ST72-IV isolates, which were susceptible to fluoroquinolones, gentamicin, rifampicin, and cotrimoxazole, were presumptively identified among 4667 MRSA isolates and then confirmed by SCCmec typing and multilocus sequence typing. A total of 124 cases of ST72-IV infections were analysed.
FINDINGS: The annual incidence of infections by ST72-IV per 100,000 admissions increased from 45.5 to 66.3 cases during 2007-2009. The most frequently occurring type of infection was skin and soft tissue infection (SSTI) (46.0%), followed by pneumonia (27.4%) and bone and joint infection (9.7%). Surgical site infection accounted for 22.6% and 32.5% of community-onset (CO) healthcare-associated infection and hospital-onset (HO) infection, respectively. Pneumonia was most frequent (45.0%) among HO infection. Multivariate analysis showed that pneumonia increased the odds of all-cause mortality (odds ratio: 18.8; 95% confidence interval: 2.6-133.9) compared with other types of infection.
CONCLUSIONS: Increasing trends were observed in annual incidence of CO and HO infections by ST72-IV in Korea. Pneumonia was the most frequent among HO infection and was associated with higher mortality. These findings pose important implications for successful antibiotic therapy and infection control in the era of CA-MRSA.
Copyright © 2012 The Healthcare Infection Society. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22652522     DOI: 10.1016/j.jhin.2012.04.018

Source DB:  PubMed          Journal:  J Hosp Infect        ISSN: 0195-6701            Impact factor:   3.926


  18 in total

1.  Development of EBV-encoded small RNA targeted PCR to classify EBV positive diffuse large B-cell lymphoma (DLBCL) of the elderly.

Authors:  Jaewang Lee; Min Park; Min Ho Lee; Hyun Jun Woo; Hyun-Woo Kim; Ji Yeong Yang; Yong-Bin Eom; Sa-Hyun Kim; Changyoung Yoo; Jong-Bae Kim
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01

2.  Dual-site sampling improved detection rates for MRSA colonization in patients with cutaneous abscesses.

Authors:  L May; C McCann; G Brooks; R Rothman; L Miller; J Jordan
Journal:  Diagn Microbiol Infect Dis       Date:  2014-05-20       Impact factor: 2.803

3.  Characteristics of the community-genotype sequence type 72 methicillin-resistant Staphylococcus aureus isolates that underlie their persistence in hospitals.

Authors:  Eun-Jeong Joo; Ji-Young Choi; Doo Ryeon Chung; Jae-Hoon Song; Kwan Soo Ko
Journal:  J Microbiol       Date:  2016-05-27       Impact factor: 3.422

Review 4.  Methicillin-Resistant Staphylococcus aureus: Molecular Characterization, Evolution, and Epidemiology.

Authors:  Sahreena Lakhundi; Kunyan Zhang
Journal:  Clin Microbiol Rev       Date:  2018-09-12       Impact factor: 26.132

5.  Community-Acquired Necrotizing Pneumonia Caused by ST72-SCCmec Type IV-Methicillin-Resistant Staphylococcus aureus in Korea.

Authors:  Ji-Won Hwang; Eun-Jeong Joo; Jung Min Ha; Woojoo Lee; Eun Kim; Sehyo Yune; Doo Ryeon Chung; Kyeongman Jeon
Journal:  Tuberc Respir Dis (Seoul)       Date:  2013-08-30

6.  Oral Antimicrobial Therapy: Efficacy and Safety for Methicillin-Resistant Staphylococcus aureus Infections and Its Impact on the Length of Hospital Stay.

Authors:  Young Kyung Yoon; Eu Suk Kim; Jian Hur; Shinwon Lee; Shin Woo Kim; Jin Won Cheong; Eun Ju Choo; Hong Bin Kim
Journal:  Infect Chemother       Date:  2014-09-24

7.  Emergence of Community-Genotype Methicillin-Resistant Staphylococcus aureus in Korean Hospitals: Clinical Characteristics of Nosocomial Infections by Community-Genotype Strain.

Authors:  Eun Jeong Joo; Doo Ryeon Chung; So Hyun Kim; Jin Yang Baek; Nam Yong Lee; Sun Young Cho; Young Eun Ha; Cheol In Kang; Kyong Ran Peck; Jae Hoon Song
Journal:  Infect Chemother       Date:  2017-05-26

8.  Comparison of subsequent infection in methicillin-resistant Staphylococcus aureus nasal carriers between ST72 community-genotype and hospital genotypes: a retrospective cohort study.

Authors:  So Yeon Park; Doo Ryeon Chung; Yu Ri Kang; So Hyun Kim; Sun Young Cho; Young Eun Ha; Cheol-In Kang; Kyong Ran Peck; Jae-Hoon Song
Journal:  Antimicrob Resist Infect Control       Date:  2017-06-12       Impact factor: 4.887

9.  The recent emergence in hospitals of multidrug-resistant community-associated sequence type 1 and spa type t127 methicillin-resistant Staphylococcus aureus investigated by whole-genome sequencing: Implications for screening.

Authors:  Megan R Earls; Peter M Kinnevey; Gráinne I Brennan; Alexandros Lazaris; Mairead Skally; Brian O'Connell; Hilary Humphreys; Anna C Shore; David C Coleman
Journal:  PLoS One       Date:  2017-04-11       Impact factor: 3.240

10.  Clinical and epidemiological factors associated with methicillin resistance in community-onset invasive Staphylococcus aureus infections: prospective multicenter cross-sectional study in Korea.

Authors:  Eu Suk Kim; Hong Bin Kim; Gayeon Kim; Kye-Hyung Kim; Kyung-Hwa Park; Shinwon Lee; Young Hwa Choi; Jongyoun Yi; Chung Jong Kim; Kyoung-Ho Song; Pyoeng Gyun Choe; Nam-Joong Kim; Yeong-Seon Lee; Myoung-Don Oh
Journal:  PLoS One       Date:  2014-12-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.